Assenagon Asset Management’s Nuvation Bio NUVB Stock Holding History

Assenagon Asset Management’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-18,209	Closed	-$35.5K	–	1243
2025 Q2	$35.5K	Sell	18,209 -5,806	-24%	-$12.1K	﹤0.01%	1145
2025 Q1	$42.3K	Sell	24,015 -105,348	-81%	-$240K	﹤0.01%	1139
2024 Q4	$344K	Sell	129,363 -309,176	-71%	-$796K	﹤0.01%	1233
2024 Q3	$1M	Sell	438,539 -135,871	-24%	-$414K	﹤0.01%	1129
2024 Q2	$1.68M	Hold	574,410	–	–	﹤0.01%	960
2024 Q1	$2.09M	Sell	574,410 -164,421	-22%	-$316K	﹤0.01%	882
2023 Q4	$1.12M	Buy	738,831 +507,452	+219%	+$653K	﹤0.01%	1073
2023 Q3	$310K	Sell	231,379 -42,335	-15%	-$70.5K	﹤0.01%	1281
2023 Q2	$493K	Sell	273,714 -208,519	-43%	-$354K	﹤0.01%	1132
2023 Q1	$801K	Buy	482,233 +219,617	+84%	+$445K	﹤0.01%	1110
2022 Q4	$504K	Buy	+262,616	New	+$531K	﹤0.01%	1170

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Assenagon Asset Management's NUVB Position: Q3 2025 in Review

Assenagon Asset Management sold out of Nuvation Bio (NUVB) in Q3 2025, closing a stake of 18,209 shares — an estimated $35.5K sold.

Assenagon Asset Management first reported a position in NUVB in Q4 2022 and held it in 11 quarters. The position peaked at $2.09M in Q1 2024. 203 funds tracked by Wall St. Rank hold NUVB as of Q3 2025.

Assenagon Asset Management reported no remaining Nuvation Bio position as of Q3 2025 after selling out during the quarter.
Assenagon Asset Management sold 18,209 Nuvation Bio shares in Q3 2025, an estimated $35.5K.
Assenagon Asset Management first reported a position in Nuvation Bio in Q4 2022 and held it in 11 quarters.
Assenagon Asset Management's Nuvation Bio position peaked at $2.09M in Q1 2024.
203 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2025.

Based on Assenagon Asset Management's 13F filing for Q3 2025, filed 7 Oct 2025.